COG A Randomized Phase II Study of Bevacizumab (NSC 704865; BB-IND# 7921) Combined with Vincristine; Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma Pediatric CIRB Completed Completed